IP Library › Granted Patent US 12,324,441
Granted Patent B2
US 12,324,441 · App. 18/308,934 · Granted Jun 10, 2025

Hyperimmunized egg product for treatment or prevention of coronavirus infection

Inventors: Subramanian V. Iyer (Royal Palm Beach, FL); Satishchandran Chandrasekhar (Jupiter, FL); Uday Saxena (Bengaluru, IN); Gopi Kadiyala (Karnataka, IN)
Assignee: Lay Sciences, Inc.
A23B5/03A23B5/00A61K39/215C07K16/1002C07K16/1003A61K2039/552
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,324,441
App. No.
18/308,934
Granted
Jun 10, 2025
Kind
B2
Abstract

In one aspect, the present disclosure is directed to a method for preventing or treating a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a hyperimmunized egg product obtained from an egg-producing animal, thereby preventing or treating coronavirus infection in the subject, wherein the hyperimmunized egg product comprises a therapeutically effective amount of one or more antibodies to the coronavirus. The present disclosure is also directed to hyperimmunized eggs and egg products produced by an animal that has been hyperimmunized with an antigen selected from i) a spike (S) protein, an S1 subunit protein, an S2 subunit protein, a receptor binding domain (RBD), and an immunogenic fragment thereof; ii) a nucleocapsid (N) protein, and an immunogenic fragment thereof; iii) a human ACE2 receptor protein, and an immunogenic fragment thereof; and iv) a human coronavirus selected from the group consisting of SARS-CoV, MERS-CoV, SARS-CoV-2, HCoV-HKU1, HCoV-NL63, HCoV-OC43 and HCoV-229E. Methods of preparing the hyperimmunized eggs and egg products are also disclosed.

Claims (17)

1. A hyperimmunized egg produced by an animal that has been hyperimmunized with an antigen consisting of the amino acid sequence of SEQ ID NO: 19,

wherein the level of antibodies to the antigen in the hyperimmunized egg is increased relative to an egg from an animal that has not been hyperimmunized.

2. The hyperimmunized egg of claim 1 , wherein the antibodies in the hyperimmunized egg have a titer of at least 80,000 as measured by optical density.

3. A hyperimmunized egg product obtained from the hyperimmunized egg of claim 1 , wherein the hyperimmunized egg product is whole egg, egg yolk, or the purified or partially purified IgY antibody fraction to SARS-COV-2 from the hyperimmunized egg.

4. A pharmaceutical composition comprising the hyperimmunized egg product of claim 3 and a pharmaceutically acceptable carrier.

5. The pharmaceutical composition of claim 4 formulated for oral, nasal or ocular administration.

6. The pharmaceutical composition of claim 5 , wherein:

the pharmaceutical composition is formulated for administration to the subject as an oral rinse, by inhalation, by nasal drops or by eye drops; or

the pharmaceutical composition is a liquid, a freeze-dried powder, or formulated to be administered as a spray.

7. The pharmaceutical composition of claim 4 , wherein the pharmaceutically acceptable carrier comprises a compound that is generally recognized as safe (GRAS) and an excipient that increases solubility, stability and/or dissolution of the pharmaceutical composition relative to the pharmaceutical composition lacking the compound.

8. The pharmaceutical composition of claim 6 , wherein the hyperimmunized egg product is formulated in nanoparticles or in an emulsion.

9. The hyperimmunized egg product of claim 3 , wherein the hyperimmunized egg product is in a form of nanoparticles having a diameter less than 1000 nm.

10. The hyperimmunized egg product of claim 3 , wherein the hyperimmunized egg product is in a form of microparticles having a diameter in the range of about 0.1 to 10 microns.

11. The hyperimmunized egg product of claim 3 , wherein the hyperimmunized egg product is in a form of microparticles having a diameter in the range of about 10 to 100 microns.

12. The hyperimmunized egg product of claim 3 , wherein the hyperimmunized egg product is encapsulated in an encapsulating material.

13. The hyperimmunized egg product of claim 3 , wherein the hyperimmunized egg product is mixed with an agent that increases flow properties of the hyperimmunized egg product relative to the hyperimmunized egg product lacking the agent.

14. The hyperimmunized egg product of claim 3 , wherein the hyperimmunized egg product is in a form of nanoparticles having a diameter in the range of about 10 to 1000 nm.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 4, 2023
From: IYER, SUBRAMANIAN V.
To: PRODIGY BIOTECH, INC.
Reel/Frame 063538/0456 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 4, 2023
From: CHANDRASEKHAR, SATISHCHANDRAN
To: PRODIGY BIOTECH, INC.
Reel/Frame 063538/0489 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 4, 2023
From: SAXENA, UDAY
To: REAGENE BIOSCIENCES PVT LTD
Reel/Frame 063538/0498 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 4, 2023
From: KADIYALA, GOPI
To: KYNTOX BIOTECH INDIA PVT LTD
Reel/Frame 063538/0519 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 4, 2023
From: PRODIGY BIOTECH, INC.
To: LAY SCIENCES, INC.
Reel/Frame 063538/0522 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 4, 2023
From: REAGENE BIOSCIENCES PVT LTD
To: LAY SCIENCES, INC.
Reel/Frame 063538/0544 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 4, 2023
From: KYNTOX BIOTECH INDIA PVT LTD
To: LAY SCIENCES, INC.
Reel/Frame 063538/0572 →
Continuity (3)
Continuation 17693280 · Mar 11, 2022
Provisional Application 63160155 · Mar 12, 2021
Related Publication 20230285547A1 · Sep 14, 2023
References Cited (37)
US 4748018A · Stolle et al. · 1988 [cited by applicant]
US 5367054A · Lee · 1994 [cited by applicant]
US 5772999A · Greenblatt et al. · 1998 [cited by applicant]
US 6803035B2 · Greenblatt et al. · 2004 [cited by applicant]
US 7105158B1 · D'Souza et al. · 2006 [cited by applicant]
US 10434116B2 · Frieman et al. · 2019 [cited by applicant]
US 11701423B2 · Iyer · 2023 [cited by examiner]
US 20040156857A1 · Adalsteinsson et al. · 2004 [cited by applicant]
US 20210347858A1 · Starzl · 2021 [cited by applicant]
CDC's Interim Clinical Considerations, Jul. 20, 2022, from https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html, accessed Aug. 9, 2022, 30 page printout (2022). [cited by applicant]
Elzoghby et al., “Albumin-based nanoparticles as potential controlled release drug delivery systems,” Journal of Controlled Release, 157:168-182 (2012). [cited by applicant]
Fertel et al., “Formation of Antibodies to Prostaglandins in the Yolk of Chicken Eggs,” Biochemical and Biophysical Research Communications, 102: 1028-1033 (1981). [cited by applicant]
Gallaher et al., “Analysis of Wuhan Coronavirus: Deja Vu,” Virological.org 63, (2020), 88 pages. [cited by applicant]
Gallaher et al., “Analysis of Wuhan Coronavirus: Deja Vu Update Feb. 7, 2020,” Virological.org 63, (2020), 97 pages. [cited by applicant]
Jensenius et al., “Eggs: Conveniently Packaged Antibodies. Methods for Purification of Yolk IgG,” Journal of Immunological Methods, 46: 63-68 (1981). [cited by applicant]
Lebacq-Verheyden et al., “Quantification and Distribution of Chicken Immunoglobulins IgA, IgM and IgG in Serum and Secretions,” Immunology, 27: 683-692 (1974). [cited by applicant]
Leslie et al., “Phylogeny of Immunoglobulin Structure and Function: III. Immunoglobulins of the Chicken,” Journal of Experimental Medicine, 130: 1337-1352 (1969). [cited by applicant]
Tse et al., “A Novel Activiation Mechanism of Avian Influenza Virus H9N2 by Furin,” Journal of Virology, 88:1673-1683 (2014). [cited by applicant]
Mathiowitz et al., “Microencapsulation,” in Encyclopedia of Controlled Drug Delivery, vol. 2, pp. 495-546, 1999, John Wiley & Sons, Inc. New York, N.Y. [cited by applicant]
Matsuyama et al., “Middle East Respiratory Syndrome Coronavirus Spike Protein Is Not Activated Directly by Cellular Furin During Viral Entry into Target Cells,” Journal of Virology, vol. 92, Issue 19, 2018 (e00683-18), … [cited by applicant]
Polson et al., “Antibodies to Proteins From Yolk of Immunized Hens,” Immunological Communications, 9: 495-514 (1980). [cited by applicant]
Wan et al., “Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis based on Decade-Long Structural Studies of SARS Coronavirus,” Journal of Virology, vol. 94, Issue 7, 2020 (e00127-20), 9 pages. [cited by applicant]
Wrapp et al., “Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation,” Science, 367: 1260-1263 (2020). [cited by applicant]
Bonnin et al., “HCov-229E spike protein fusion activation by trypsin-like serine proteases is mediated by proteolytic processing in the S2′ region,” Journal of General Virology, 99:908-912 (2018). [cited by applicant]
Carlander et al., “Chicken Antibodies: A Clinical Chemistry Perspective,” Upsala Journal of Medical Sciences, 104 (3): 179-189 (1999). [cited by applicant]
De Haan et al., “Cleavage of Group 1 Coronavirus Spike Proteins: How Furin Cleavage Is Traded Off against Heparan Sulfate Binding upon Cell Culture Adaptation,” Journal of Virology, 82(12):6078-6083 (2008). [cited by applicant]
Gralinski et al., “Return of the Coronavirus: 2019-nCoV,” Viruses, 12:135 (2020), doi:10.3390/v12020135, 8 pages. [cited by applicant]
Hoffmann et al., “SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor,” Cell, 181:271-280.e1-e5 (2020). [cited by applicant]
Jia et al., “ACE2 Receptor Expression and Severe Acute Respiratory Syndrome Coronavirus Infection Depend on Differentiation of Human Airway Epithelia,” Journal of Virology, 79(23):14614-14621 (2005). [cited by applicant]
Lin et al., “Identification of residues in the receptor-binding domain (RBD) of the spike protein of human coronavirus NL63 that are critical for the RBD-ACE2 receptor interaction,” Journal of General Virology, 89:1015-… [cited by applicant]
Lucchese, “Epitopes for a 2019-nCoV vaccine,” Cellular & Molecular Immunology, 17:539-540 (2020). [cited by applicant]
Meulenaer et al., “Isolation and Purification of Chicken Egg yolk Immunoglobulins: A Review,” Food and Agricultral Immunology, 13:275-288 (2001). [cited by applicant]
Millet et al., “Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein,” Proceedings of the National Academy of Sciences of the U.S.A., 111(42): 15… [cited by applicant]
Yang et al., “A novel and convenient method to immunize animals: inclusion bodies from recombinant bacteria as antigen to directly immunize animals,” African Journal Biotechnology, 10(41):8146-8150 (2011). [cited by applicant]
Andersen et al., “The proximal origin of SARS-CoV-2,” Nature Medicine, 26: 450-452 (2020). [cited by applicant]
GenBank Accession No. MN908947.3, “Severe acute respiratory syndrome coronavirus 2 isolate Wuhan-Hu-1, complete genome,” Published: Mar. 18, 2020, 10 pages. [cited by applicant]
Saxena et al., “In silico and in vitro Demonstration of Homoharrintonine's Antagonism of RBD-ACE2 Binding and its Anti-inflammatory and anti-thrombogenic Properties in a 3D human vascular lung model,” bioRxiv 2021.05.02… [cited by applicant]